NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $33.63
  • Forecasted Upside: 299.35 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.42
▼ -0.05 (-0.59%)

This chart shows the closing price for DCPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Deciphera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCPH

Analyst Price Target is $33.63
▲ +299.35% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $33.63, with a high forecast of $78.00 and a low forecast of $10.00. The average price target represents a 299.35% upside from the last price of $8.42.

This chart shows the closing price for DCPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in Deciphera Pharmaceuticals. This rating has held steady since October 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
12/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
1/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2021HC WainwrightLower Price TargetBuy$25.00 ➝ $15.00High
11/30/2021Piper SandlerLower Price TargetNeutral$14.00 ➝ $11.00High
11/22/2021JonestradingReiterated RatingSellHigh
11/15/2021SVB LeerinkReiterated RatingBuy$70.00Medium
11/8/2021HC WainwrightLower Price TargetBuy$70.00 ➝ $25.00High
11/8/2021BarclaysDowngradeOverweight ➝ Equal Weight$50.00 ➝ $11.00High
11/7/2021Stifel NicolausDowngradeBuy ➝ Hold$60.00 ➝ $10.00High
11/5/2021Piper SandlerDowngradeOverweight ➝ NeutralN/A
11/5/2021GuggenheimDowngradeBuy ➝ NeutralN/A
11/5/2021Truist FinancialDowngradeBuy ➝ Hold$65.00 ➝ $10.00N/A
11/5/2021JMP SecuritiesLower Price TargetMarket Outperform$70.00 ➝ $64.00N/A
10/4/2021Truist FinancialLower Price TargetBuy$84.00 ➝ $65.00Medium
9/29/2021Stifel NicolausInitiated CoverageBuyLow
9/20/2021HC WainwrightReiterated RatingBuy$70.00Low
9/20/2021JMP SecuritiesReiterated RatingBuy$70.00Low
8/4/2021HC WainwrightLower Price TargetPositive ➝ Buy$75.00 ➝ $70.00High
5/5/2021HC WainwrightLower Price TargetBuy$80.00 ➝ $75.00High
5/5/2021BarclaysLower Price TargetOverweight$70.00 ➝ $65.00High
5/5/2021Piper SandlerLower Price TargetOverweight$75.00 ➝ $60.00High
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$78.00High
2/10/2021BarclaysLower Price TargetOverweight$85.00 ➝ $70.00Low
2/10/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$70.00Low
12/2/2020Stifel NicolausInitiated CoverageBuy$75.00Medium
11/12/2020SVB LeerinkBoost Price TargetMarket Perform$58.00 ➝ $70.00Low
9/14/2020SVB LeerinkBoost Price TargetMarket Perform$54.00 ➝ $58.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
8/5/2020SVB LeerinkLower Price TargetMarket Perform$55.00 ➝ $54.00Low
6/12/2020GuggenheimReiterated RatingBuy$70.00High
5/18/2020SunTrust BanksBoost Price TargetBuy$82.00 ➝ $91.00Medium
5/18/2020BarclaysReiterated RatingBuy$80.00 ➝ $85.00Medium
5/7/2020Nomura InstinetDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
5/6/2020NomuraDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
5/6/2020JPMorgan Chase & Co.Lower Price TargetOverweight$50.00 ➝ $49.00High
5/6/2020HC WainwrightBoost Price TargetBuy$60.00 ➝ $80.00High
4/29/2020SunTrust BanksBoost Price TargetBuy$77.00 ➝ $82.00Medium
4/29/2020SVB LeerinkBoost Price TargetHold$50.00 ➝ $55.00Medium
3/4/2020BarclaysInitiated CoverageOverweight$70.00High
1/22/2020Piper SandlerReiterated RatingBuy$75.00Low
1/21/2020Nomura SecuritiesBoost Price TargetBuy$57.00 ➝ $84.00Low
1/15/2020JMP SecuritiesReiterated RatingBuy$70.00Low
1/10/2020SunTrust BanksInitiated CoverageBuy$77.00Low
12/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$55.00 ➝ $75.00Low
12/20/2019Jefferies Financial GroupBoost Price TargetBuy$53.00 ➝ $77.00Medium
11/5/2019JMP SecuritiesBoost Price TargetOutperform ➝ Market Outperform$45.00 ➝ $54.00Low
10/29/2019SVB LeerinkUpgradeUnderperform ➝ Market Perform$29.00 ➝ $34.00Medium
10/22/2019JMP SecuritiesInitiated CoverageOutperformLow
10/3/2019HC WainwrightInitiated CoverageBuy$60.00High
9/30/2019Piper Jaffray CompaniesSet Price TargetBuy$55.00High
9/30/2019Jefferies Financial GroupInitiated CoverageBuy$47.00High
8/14/2019SunTrust BanksBoost Price TargetPositive ➝ Buy$60.00Low
8/14/2019SVB LeerinkReiterated RatingUnderperform ➝ Positive$20.00 ➝ $29.00High
8/14/2019Cantor FitzgeraldBoost Price TargetOverweight$43.00 ➝ $55.00High
8/13/2019GuggenheimBoost Price TargetBuy$44.00 ➝ $66.00High
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$42.00Low
6/3/2019Piper Jaffray CompaniesBoost Price TargetOverweight$50.00 ➝ $55.00High
1/1/2019B. RileyDowngradeBuy ➝ NeutralHigh
12/31/2018B. RileyInitiated CoverageNeutral ➝ Buy$27.00 ➝ $34.00High
12/20/2018Cantor FitzgeraldReiterated RatingBuy$53.00Medium
11/16/2018SVB LeerinkLower Price TargetUnderperform$28.00 ➝ $20.00Medium
10/3/2018Cantor FitzgeraldReiterated RatingBuy$53.00Medium
9/24/2018SVB LeerinkInitiated CoverageUnderperform ➝ Underperform$28.00Low
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/6/2018Cantor FitzgeraldInitiated CoverageBuy$53.00High
8/29/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$47.00Medium
8/22/2018Cantor FitzgeraldInitiated CoverageOverweight$53.00Medium
7/5/2018SunTrust BanksInitiated CoverageBuyHigh
6/19/2018JMP SecuritiesBoost Price TargetOutperform$65.00Low
6/19/2018B. RileyDowngradeBuy ➝ Neutral$43.00Medium
6/12/2018Piper Jaffray CompaniesBoost Price TargetOverweight$50.00Low
6/4/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $33.00High
5/9/2018B. RileyLower Price TargetBuy ➝ Buy$52.00 ➝ $43.00High
2/16/2018B. RileyInitiated CoverageBuy ➝ Buy$43.00High
10/23/2017Nomura SecuritiesInitiated CoverageBuy ➝ Buy$57.00N/A
10/23/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$35.00N/A
10/23/2017Nomura InstinetInitiated CoverageBuy$57.00N/A
10/23/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$38.00N/A
10/23/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$30.00N/A
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/27/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Deciphera Pharmaceuticals logo
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $8.42
Low: $8.05
High: $8.62

50 Day Range

MA: $8.98
Low: $7.70
High: $11.11

52 Week Range

Now: $8.42
Low: $7.63
High: $52.43

Volume

1,339,694 shs

Average Volume

1,734,881 shs

Market Capitalization

$492.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Credit Suisse Group AG, Guggenheim, HC Wainwright, JMP Securities, Jonestrading, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for DCPH.

What is the current price target for Deciphera Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $33.63, suggesting a possible upside of 299.3%. Credit Suisse Group AG has the highest price target set, predicting DCPH will reach $78.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $10.00 for Deciphera Pharmaceuticals in the next year.
View the latest price targets for DCPH.

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals currently has 1 sell rating, 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DCPH, but not buy more shares or sell existing shares.
View the latest ratings for DCPH.

How do I contact Deciphera Pharmaceuticals' investor relations team?

Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is (781) 209-6400 and its investor relations email address is [email protected] The official website for Deciphera Pharmaceuticals is www.deciphera.com.